PartneringPartnering
- Successful commercialisation, development and research partnerships
- Promising candidates ready for out-licensing now
- In-licensing opportunities sought for neurology, pain and oncology
Partnering is an integral part of our strategy at Vernalis. We actively in-license and out-license programmes as well as enter into research and development collaborations. We seek to in-license pre-clinical and early stage clinical programmes to complement our own development pipeline and drug discovery programmes.
Why partner with Vernalis?
Established track-record with a number of large pharmaceutical companies
Partners include GSK, Lundbeck, Novartis, Servier and others
In-licensing opportunities
Vernalis actively seeks additional pre-clinical and early stage clinical programmes
Our key therapeutic areas include oncology, pain and neurology
Out-licensing opportunities
We have a number of promising partnership opportunities
Sharing the risks and rewards of late stage development with suitably qualified partners
Research collaboration opportunities
Our expertise is in fragment and structure based drug discovery
Add our approach to your research programmes
Conferences
Vernalis attends several partnering and scientific community meetings
See the conferences we’re scheduled to attend and view conference presentations
Current partners
Who already works with Vernalis?
See the full list of current partners and the projects we’re engaged on
Latest News
Tuesday, 17 January 2012
Vernalis and Servier Sign Third Oncology Collaboration
Vernalis plc, Servier announce they have entered into a new three-year joint oncology collaboration focused on the discovery of drugs for a new undisclosed target.
Product Pipeline
See at a glance what Vernalis has in development